v3.25.1
Interest-bearing loans and borrowings - Narrative (Details)
3 Months Ended
Feb. 02, 2024
USD ($)
Nov. 08, 2022
USD ($)
tranch
Mar. 31, 2025
USD ($)
d
shares
$ / shares
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Debt Instrument [Line Items]            
Proceeds from issue of convertible loan notes     $ 0   $ 402,500,000  
Convertible debt | Convertible senior notes            
Debt Instrument [Line Items]            
Principal Amount $ 402,500,000   $ 402,500,000     $ 402,500,000
Option to purchase additional notes 52,500,000          
Proceeds from issue of convertible loan notes 389,100,000          
Lender fees and issuance costs $ 13,400,000          
Interest rate on notes 2.50%   3.06%      
Conversion ratio 10.5601          
Debt instrument converted amount     $ 1,000      
Conversion price (in USD per share) | $ / shares     $ 94.70      
Convertible number of equity instruments (in shares) | shares     5,950,600      
Threshold percentage of stock price trigger     130.00%      
Threshold trading days | d     20      
Threshold consecutive trading days | d     30      
Percentage of redemption price principal amount     100.00%      
Line of credit | Pharmakon loan            
Debt Instrument [Line Items]            
Number of tranches in which loans funded | tranch   2        
Line of credit | Pharmakon loan, first tranche            
Debt Instrument [Line Items]            
Long term borrowing fixed interest rate   9.75%        
Loans payable | Pharmakon loan            
Debt Instrument [Line Items]            
Principal Amount   $ 100,000,000        
Debt Instrument, Fee Payable       $ 1,250,000    
Loans payable | Pharmakon loan, first tranche            
Debt Instrument [Line Items]            
Principal Amount   50,000,000        
Loans payable | Pharmakon loan, second tranche            
Debt Instrument [Line Items]            
Principal Amount   $ 50,000,000